HK1199470A1 - Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof egfr - Google Patents

Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof egfr

Info

Publication number
HK1199470A1
HK1199470A1 HK14112920.4A HK14112920A HK1199470A1 HK 1199470 A1 HK1199470 A1 HK 1199470A1 HK 14112920 A HK14112920 A HK 14112920A HK 1199470 A1 HK1199470 A1 HK 1199470A1
Authority
HK
Hong Kong
Prior art keywords
egfr
antigen binding
binding molecules
vectors encoding
encoding same
Prior art date
Application number
HK14112920.4A
Other languages
English (en)
Chinese (zh)
Inventor
巴勃羅‧烏馬納
埃克哈德‧默斯納
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36777599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1199470(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of HK1199470A1 publication Critical patent/HK1199470A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK14112920.4A 2005-02-07 2008-05-13 Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof egfr HK1199470A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65011505P 2005-02-07 2005-02-07

Publications (1)

Publication Number Publication Date
HK1199470A1 true HK1199470A1 (en) 2015-07-03

Family

ID=36777599

Family Applications (2)

Application Number Title Priority Date Filing Date
HK14112920.4A HK1199470A1 (en) 2005-02-07 2008-05-13 Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof egfr
HK08105244.5A HK1110873A1 (en) 2005-02-07 2008-05-13 Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof egfr

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK08105244.5A HK1110873A1 (en) 2005-02-07 2008-05-13 Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof egfr

Country Status (28)

Country Link
US (8) US7722867B2 (pl)
EP (4) EP1871805B1 (pl)
JP (2) JP5336089B2 (pl)
KR (2) KR101569300B1 (pl)
CN (2) CN103981190A (pl)
AR (1) AR052285A1 (pl)
AU (1) AU2006211037B2 (pl)
BR (1) BRPI0607315B1 (pl)
CA (1) CA2596835C (pl)
CR (2) CR9236A (pl)
DK (1) DK1871805T3 (pl)
ES (1) ES2755976T3 (pl)
HK (2) HK1199470A1 (pl)
HR (1) HRP20192134T1 (pl)
IL (1) IL184498A (pl)
LT (1) LT1871805T (pl)
MA (1) MA29279B1 (pl)
MX (1) MX2007008619A (pl)
NO (1) NO20073662L (pl)
NZ (1) NZ556286A (pl)
PL (1) PL1871805T3 (pl)
PT (1) PT1871805T (pl)
RS (1) RS59761B1 (pl)
RU (2) RU2488597C2 (pl)
SI (1) SI1871805T1 (pl)
TW (1) TWI387602B (pl)
UA (1) UA95068C2 (pl)
WO (1) WO2006082515A2 (pl)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
WO2006082515A2 (en) 2005-02-07 2006-08-10 Glycart Biotechnology Ag Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
AR062223A1 (es) * 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
MX2009012838A (es) 2007-06-06 2009-12-11 Hoffmann La Roche Composicion de un primer anticuerpo monoclonal no marcado que se aglutina a un antigeno tumoral y a un segundo anticuerpo monoclonal de reaccion no cruzada marcado con un marcador fluorescsente del infrarrojo proximo.
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
RU2011116112A (ru) * 2008-09-26 2012-11-10 Роше Гликарт Аг (Ch) Биспецифические анти-egfr/анти-igf-1r антитела
AR075982A1 (es) * 2009-03-31 2011-05-11 Roche Glycart Ag Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
CA2754646A1 (en) * 2009-03-31 2010-10-07 Roche Glycart Ag Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
WO2010112194A1 (en) 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
US20100256340A1 (en) 2009-04-07 2010-10-07 Ulrich Brinkmann Trivalent, bispecific antibodies
AU2010233993A1 (en) 2009-04-07 2011-09-08 Roche Glycart Ag Bispecific anti-ErbB-1/anti-c-Met antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US20120302737A1 (en) 2009-09-16 2012-11-29 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
US20110158987A1 (en) 2009-12-29 2011-06-30 F. Hoffmann-Laroche Ag Novel antibody formulation
CN102906115A (zh) * 2010-01-11 2013-01-30 阿雷克森制药公司 在经抗cd200抗体治疗的人体内的免疫调节效应的生物标记
WO2011101328A2 (en) * 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
CN101875697B (zh) * 2010-04-15 2014-04-30 北京天广实生物技术股份有限公司 新型抗egfr人源抗体tgm10的设计及其应用
KR101586128B1 (ko) 2010-08-24 2016-01-15 에프. 호프만-라 로슈 아게 디술피드 안정화 ― Ｆｖ 단편을 포함하는 이중특이적 항체
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
CN102153647B (zh) * 2011-01-27 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 一种抗egfr人源化抗体l3-h3及其编码基因与应用
RU2013139267A (ru) 2011-02-10 2015-03-20 Рош Гликарт Аг Улучшенная иммунотерапия
EP2681240B1 (en) 2011-02-28 2017-08-16 F. Hoffmann-La Roche AG Monovalent antigen binding proteins
RU2607038C2 (ru) 2011-02-28 2017-01-10 Ф. Хоффманн-Ля Рош Аг Антигенсвязывающие белки
WO2012121167A1 (ja) * 2011-03-04 2012-09-13 日本電気株式会社 個体識別システム、個体識別方法及びそれらに用いられる装置、プログラム
CA2844540C (en) 2011-08-23 2018-10-16 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
CA2837975C (en) 2011-08-23 2022-04-05 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
PL2748202T3 (pl) 2011-08-23 2018-12-31 Roche Glycart Ag Dwuswoiste cząsteczki wiążące antygen
AU2012300279A1 (en) 2011-08-26 2014-04-03 Merrimack Pharmaceuticals, Inc. Tandem Fc bispecific antibodies
BR112014006537A2 (pt) 2011-09-23 2017-11-28 Roche Glycart Ag anticorpos biespecíficos, formulação farmacêutica, usos de um anticorpo biespecífico, método de tratamento, ácido nucleico, vetores de expressão, célula hospedeira e método para a produção de um anticorpo biespecífico
WO2013113641A1 (en) 2012-01-31 2013-08-08 Roche Glycart Ag Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
CN104105711B (zh) 2012-02-10 2018-11-30 弗·哈夫曼-拉罗切有限公司 单链抗体及其他异多聚体
RU2014138586A (ru) 2012-03-02 2016-04-20 Рош Гликарт Аг Прогностический биомаркер для лечения рака антителами с повышенной антителозависимой клеточной цитотоксичностью
CN110317259A (zh) * 2012-03-27 2019-10-11 株式会社绿十字 表皮生长因子受体表面抗原的表位及其用途
WO2013173255A2 (en) * 2012-05-17 2013-11-21 Sorrento Therapeutics Inc. Antigen binding proteins that bind egfr
CN104411718B (zh) 2012-06-27 2018-04-24 弗·哈夫曼-拉罗切有限公司 用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途
CN104395339A (zh) 2012-06-27 2015-03-04 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
PL3434695T3 (pl) 2012-08-07 2021-05-17 Roche Glycart Ag Ulepszona immunoterapia
KR20150064068A (ko) 2012-10-08 2015-06-10 로슈 글리카트 아게 2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2014114595A1 (en) 2013-01-23 2014-07-31 Roche Glycart Ag Predictive biomarker for cancer treatment with adcc-enhanced antibodies
EP3708584A1 (en) 2013-02-26 2020-09-16 Roche Glycart AG Bispecific t cell activating antigen binding molecules
CA2896370A1 (en) * 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
EP2961770A1 (en) 2013-02-26 2016-01-06 Roche Glycart AG Bispecific t cell activating antigen binding molecules
BR112015021462A2 (pt) 2013-03-06 2017-10-10 Adimab Llc anticorpos biespecíficos anti-c-met tandem fc
SG11201507743XA (en) * 2013-04-22 2015-11-27 Glycotope Gmbh Anti-cancer treatments with anti-egfr antibodies having a low fucosylation
CN105612182B (zh) 2013-10-11 2019-12-10 豪夫迈·罗氏有限公司 多特异性结构域交换共有可变轻链抗体
MX2016006301A (es) 2013-11-13 2016-12-16 Zymeworks Inc Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos.
EP3662928A1 (en) * 2014-04-10 2020-06-10 OBI Pharma Inc. Antibodies binding to tumour associated carbohydrate antigens, pharmaceutical compositions and uses thereof
BR112016030462A2 (pt) 2014-08-04 2018-01-16 F. Hoffmann-La Roche Ag moléculas de ligação, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula de ligação, composição farmacêutica, uso da molécula de ligação, método de tratamento de doenças e de indução da lise de células alvo
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
EP3659625A1 (en) 2014-10-23 2020-06-03 Innate Pharma Treatment of cancers using anti-nkg2a agents
WO2016079050A1 (en) 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
LT3221357T (lt) 2014-11-20 2020-08-25 F. Hoffmann-La Roche Ag Bendros lengvosios grandinės ir naudojimo būdai
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
WO2017055392A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
AR106365A1 (es) 2015-10-02 2018-01-10 Hoffmann La Roche Moléculas biespecíficas de unión a antígeno activadoras de células t
CN108026177B (zh) 2015-10-02 2021-11-26 豪夫迈·罗氏有限公司 双特异性抗cd19xcd3 t细胞活化性抗原结合分子
WO2017055385A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
US20180282410A1 (en) 2015-10-02 2018-10-04 Hoffmann-La Roche Inc. Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
CA2990755A1 (en) 2015-10-02 2017-04-06 F. Hoffman-La Roche Ag Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
EP3356409A2 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific t cell activating antigen binding molecules
WO2017055393A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
CA2997406C (en) 2015-12-09 2024-05-28 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release
AU2017205089B2 (en) 2016-01-08 2023-10-05 F. Hoffmann-La Roche Ag Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
KR102444614B1 (ko) 2016-03-22 2022-09-21 에프. 호프만-라 로슈 아게 프로테아제-활성화된 t 세포 이중특이적 분자
PE20231511A1 (es) 2016-03-22 2023-09-26 Hoffmann La Roche Moleculas biespecificas de celulas t activadas por proteasas que se unen especificamente al receptor 1 de folato (folr1) y cd3
WO2018060301A1 (en) 2016-09-30 2018-04-05 F. Hoffmann-La Roche Ag Bispecific antibodies against cd3
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
PE20191703A1 (es) 2017-03-27 2019-11-27 Hoffmann La Roche Formatos mejorados de receptor de union a antigeno
CA3056837A1 (en) 2017-03-27 2018-10-04 F. Hoffmann-La Roche Ag Improved antigen binding receptors
MA49033B1 (fr) 2017-04-03 2022-10-31 Hoffmann La Roche Immunoconjugué d'un anticorps contre pd-1 avec il-2 mutée ou avec il-15
SG11201909218RA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
EP3606947B1 (en) 2017-04-03 2022-12-21 F. Hoffmann-La Roche AG Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
TWI707871B (zh) 2017-04-05 2020-10-21 瑞士商赫孚孟拉羅股份公司 抗lag3抗體
CN110505883A (zh) 2017-04-13 2019-11-26 豪夫迈·罗氏有限公司 供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
CN107881160A (zh) * 2017-08-11 2018-04-06 百奥泰生物科技(广州)有限公司 一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
EP3729080B1 (en) 2017-12-21 2023-04-19 F. Hoffmann-La Roche AG Universal reporter cell assay for specificity test of novel antigen binding moieties
KR102575787B1 (ko) 2017-12-21 2023-09-08 에프. 호프만-라 로슈 아게 Hla-a2/wt1에 결합하는 항체
EP3731865A1 (en) 2017-12-29 2020-11-04 F. Hoffmann-La Roche AG Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
CR20200391A (es) 2018-02-08 2020-10-19 Genentech Inc Moléculas biespecíficas de unión al antígeno y métodos de uso
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
AU2019245243A1 (en) 2018-03-29 2020-09-03 Genentech, Inc Modulating lactogenic activity in mammalian cells
EP3802624A4 (en) * 2018-06-01 2022-03-23 Musc Foundation for Research Development GLYCAN ANALYSIS OF PROTEINS AND CELLS
TW202030204A (zh) 2018-12-21 2020-08-16 瑞士商赫孚孟拉羅股份公司 靶向腫瘤之超促效cd28抗原結合分子
WO2020127619A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Antibodies binding to cd3
AR117468A1 (es) 2018-12-21 2021-08-11 Hoffmann La Roche ANTICUERPO QUE SE UNE A VEGF Y A IL-1b Y MÉTODOS DE UTILIZACIÓN
JP2022514343A (ja) 2018-12-21 2022-02-10 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 腫瘍標的化アゴニストｃｄ２８抗原結合分子
US20220025056A1 (en) 2018-12-26 2022-01-27 Innate Pharma Leucocyte immunoglobulin-like receptor neutralizing antibodies
WO2020260329A1 (en) 2019-06-26 2020-12-30 F. Hoffmann-La Roche Ag Fusion of an antibody binding cea and 4-1bbl
JP2022538139A (ja) 2019-07-02 2022-08-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 変異体インターロイキン－２及び抗ｃｄ８抗体を含む免疫複合体
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
EP4004045A1 (en) 2019-07-31 2022-06-01 F. Hoffmann-La Roche AG Antibodies binding to gprc5d
CR20220019A (es) 2019-07-31 2022-02-11 Hoffmann La Roche Anticuerpos que se fijan a gprc5d
US20210130492A1 (en) 2019-09-18 2021-05-06 Genentech, Inc. Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
CR20220256A (es) 2019-12-18 2022-08-31 Hoffmann La Roche Anticuerpos que se unen a hla-a2/mage-a4
CN111018990A (zh) * 2020-02-10 2020-04-17 张喜田 一种新型的重组抗表皮生长因子受体单克隆抗体及其应用
CA3169908A1 (en) 2020-03-26 2021-09-30 Genentech, Inc. Modified mammalian cells having reduced host cell proteins
MX2022012541A (es) 2020-04-15 2022-11-07 Hoffmann La Roche Inmunoconjugados.
IL298038A (en) 2020-05-11 2023-01-01 Hoffmann La Roche Combined treatment with modified pbmcs and an immune couple
BR112022024996A2 (pt) 2020-06-08 2022-12-27 Hoffmann La Roche Anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, agente terapêutico, uso do anticorpo e método para tratar um indivíduo com hepatite b
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
KR20230025783A (ko) 2020-06-19 2023-02-23 에프. 호프만-라 로슈 아게 면역 활성화 Fc 도메인 결합 분자
AR122659A1 (es) 2020-06-19 2022-09-28 Hoffmann La Roche Anticuerpos biespecíficos para linfocitos t activados por proteasa
TWI811703B (zh) 2020-06-19 2023-08-11 瑞士商赫孚孟拉羅股份公司 與ｃｄ３及ｃｄ１９結合之抗體
JP2023530961A (ja) 2020-06-19 2023-07-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ３に結合する抗体
TW202216767A (zh) 2020-06-19 2022-05-01 瑞士商赫孚孟拉羅股份公司 與ＣＤ３及ＦｏｌＲ１結合之抗體
BR112022025989A2 (pt) 2020-06-23 2023-01-17 Hoffmann La Roche Moléculas, um ou mais polinucleotídeos, um ou mais vetores, célula hospedeira, método para produzir uma molécula, composição farmacêutica, uso da molécula e método para tratar uma doença
MX2022016453A (es) 2020-06-24 2023-02-01 Genentech Inc Lineas celulares resistentes a la apoptosis.
EP4172203A1 (en) 2020-06-25 2023-05-03 F. Hoffmann-La Roche AG Anti-cd3/anti-cd28 bispecific antigen binding molecules
CA3187277A1 (en) 2020-07-10 2022-01-13 F. Hoffmann-La Roche Ag Antibodies which bind to cancer cells and target radionuclides to said cells
AU2021308653A1 (en) 2020-07-17 2023-02-16 Genentech, Inc. Anti-Notch2 antibodies and methods of use
CN116234831A (zh) 2020-08-03 2023-06-06 豪夫迈·罗氏有限公司 改善的抗原结合受体
WO2022047222A2 (en) 2020-08-28 2022-03-03 Genentech, Inc. Crispr/cas9 multiplex knockout of host cell proteins
WO2022049165A1 (en) 2020-09-04 2022-03-10 F. Hoffmann-La Roche Ag Antibody that binds to vegf-a and ang2 and methods of use
AR123855A1 (es) 2020-10-20 2023-01-18 Genentech Inc Anticuerpos anti-mertk conjugados con peg y métodos de uso
JP2023547447A (ja) 2020-10-28 2023-11-10 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 改良型抗原結合受容体
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
WO2022152656A1 (en) 2021-01-12 2022-07-21 F. Hoffmann-La Roche Ag Split antibodies which bind to cancer cells and target radionuclides to said cells
KR20230131205A (ko) 2021-01-13 2023-09-12 에프. 호프만-라 로슈 아게 병용 요법
JP2024509695A (ja) 2021-02-03 2024-03-05 ジェネンテック， インコーポレイテッド 多重特異性結合タンパク質分解プラットフォームおよび使用方法
AR125074A1 (es) 2021-03-12 2023-06-07 Genentech Inc Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
EP4314032A1 (en) 2021-03-30 2024-02-07 F. Hoffmann-La Roche AG Protease-activated polypeptides
EP4326855A1 (en) 2021-04-19 2024-02-28 Genentech, Inc. Modified mammalian cells
KR20240010469A (ko) 2021-05-21 2024-01-23 제넨테크, 인크. 관심 재조합 생성물의 생성을 위한 변형된 세포
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
EP4370545A1 (en) 2021-07-12 2024-05-22 Genentech, Inc. Structures for reducing antibody-lipase binding
KR20240032889A (ko) 2021-07-14 2024-03-12 제넨테크, 인크. 항-c-c 모티프 케모카인 수용체 8(ccr8) 항체 및 사용 방법
EP4373859A1 (en) 2021-07-22 2024-05-29 F. Hoffmann-La Roche AG Heterodimeric fc domain antibodies
CN117794953A (zh) 2021-08-03 2024-03-29 豪夫迈·罗氏有限公司 双特异性抗体及使用方法
EP4416174A1 (en) 2021-10-14 2024-08-21 F. Hoffmann-La Roche AG New interleukin-7 immunoconjugates
WO2023062048A1 (en) 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag Alternative pd1-il7v immunoconjugates for the treatment of cancer
CN118302443A (zh) 2021-11-25 2024-07-05 豪夫迈·罗氏有限公司 改善的抗原结合受体
CN118284625A (zh) 2021-11-26 2024-07-02 豪夫迈·罗氏有限公司 抗tyrp1/抗cd3双特异性抗体与tyrp1特异性抗体的组合疗法
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
CN116333117B (zh) * 2021-12-16 2024-04-26 徕特康(苏州)生物制药有限公司 抗表皮生长因子受体抗体及其制备方法和用途
CN116333116B (zh) * 2021-12-16 2024-03-05 徕特康(苏州)生物制药有限公司 抗表皮生长因子受体抗体及其制备方法和用途
WO2023141445A1 (en) 2022-01-19 2023-07-27 Genentech, Inc. Anti-notch2 antibodies and conjugates and methods of use
WO2023180511A1 (en) 2022-03-25 2023-09-28 F. Hoffmann-La Roche Ag Improved chimeric receptors
TW202402810A (zh) 2022-05-11 2024-01-16 瑞士商赫孚孟拉羅股份公司 與ｖｅｇｆ—ａ及ｉｌ６結合之抗體及其使用方法
WO2024030856A2 (en) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Immunomodulatory proteins and related methods
WO2024068705A1 (en) 2022-09-29 2024-04-04 F. Hoffmann-La Roche Ag Protease-activated polypeptides
WO2024077118A2 (en) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods
WO2024077239A1 (en) 2022-10-07 2024-04-11 Genentech, Inc. Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
WO2024079009A1 (en) 2022-10-10 2024-04-18 F. Hoffmann-La Roche Ag Combination therapy of a gprc5d tcb and proteasome inhibitors
WO2024079015A1 (en) 2022-10-10 2024-04-18 F. Hoffmann-La Roche Ag Combination therapy of a gprc5d tcb and imids
WO2024079010A1 (en) 2022-10-10 2024-04-18 F. Hoffmann-La Roche Ag Combination therapy of a gprc5d tcb and cd38 antibodies
WO2024094741A1 (en) 2022-11-03 2024-05-10 F. Hoffmann-La Roche Ag Combination therapy with anti-cd19/anti-cd28 bispecific antibody
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
WO2024104933A1 (en) 2022-11-15 2024-05-23 F. Hoffmann-La Roche Ag Antigen binding molecules
WO2024155807A1 (en) 2023-01-18 2024-07-25 Genentech, Inc. Multispecific antibodies and uses thereof
WO2024153725A1 (en) 2023-01-20 2024-07-25 F. Hoffmann-La Roche Ag Recombinant fc domain - il2 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
WO2024156672A1 (en) 2023-01-25 2024-08-02 F. Hoffmann-La Roche Ag Antibodies binding to csf1r and cd3
US20240269263A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2820404A (en) 1954-11-23 1958-01-21 Kwei Chung Shu Photoprinting apparatus
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0531472T3 (da) 1991-03-06 2003-12-01 Merck Patent Gmbh Humaniserede monoklonale antistoffer
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
GB9401182D0 (en) * 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
CN102416176A (zh) 1995-07-27 2012-04-18 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
DE19746874A1 (de) 1997-10-23 1999-04-29 Qiagen Gmbh Verfahren zur Isolierung und Reinigung von Nukleinsäuren an hydrophoben Oberflächen - insbesondere unter Verwendung hydrophober Membranen
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6322980B1 (en) 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
IL145941A (en) * 1999-04-28 2007-08-19 Univ Texas Preparations and methods for the treatment of cancer by selective inhibition of VEGF
AU8822601A (en) 2000-07-31 2002-02-13 Biolex Inc Expression of biologically active polypeptides in duckweed
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20020128448A1 (en) 2000-10-20 2002-09-12 Idec Pharmaceuticals Corporation Variant IgG3 Rituxan and therapeutic use thereof
DK2163256T3 (en) * 2001-05-11 2015-12-07 Ludwig Inst For Cancer Res Ltd Specific binding proteins and use thereof
US7247301B2 (en) * 2001-06-13 2007-07-24 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US8932825B2 (en) 2001-12-27 2015-01-13 Glycofi Inc. Method to engineer mammalian-type carbohydrate structures
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US7657380B2 (en) * 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003219402B2 (en) 2002-03-19 2008-05-08 Stichting Dienst Landbouwkundig Onderzoek GnTIII (UDP-n-acethylglucosamine:beta-D mannoside beta (1,4)-N-acethylglucosaminy ltransferase III) expression in plants
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
WO2003084119A1 (en) 2002-03-28 2003-10-09 Advanced Micro Devices, Inc. Synchronization data detection unit and method
US20030190689A1 (en) 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
EP1502603A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
WO2005056606A2 (en) 2003-12-03 2005-06-23 Xencor, Inc Optimized antibodies that target the epidermal growth factor receptor
AU2003251597A1 (en) 2002-06-19 2004-01-06 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
EP1539966B1 (en) 2002-09-12 2010-06-30 Greenovation Biotech GmbH Protein production method
RU2390527C2 (ru) * 2002-09-27 2010-05-27 Ксенкор, Инк. АНТИТЕЛО, СОДЕРЖАЩЕЕ Fc-ВАРИАНТНУЮ ЧАСТЬ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНТИТЕЛО, И СПОСОБ ЛЕЧЕНИЯ МЛЕКОПИТАЮЩЕГО
US6938692B2 (en) 2002-12-17 2005-09-06 Halliburton Energy Services, Inc. Permeable cement composition and method for preparing the same
WO2004057002A2 (en) 2002-12-20 2004-07-08 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1587921B1 (en) 2003-01-22 2010-07-28 GlycArt Biotechnology AG Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
EA202091901A1 (ru) 2003-11-05 2020-11-24 Роше Гликарт Аг АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
WO2006082515A2 (en) * 2005-02-07 2006-08-10 Glycart Biotechnology Ag Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
WO2007031872A2 (en) * 2005-07-13 2007-03-22 L'oréal Keratin fibre coating composition comprising a liquid fatty phase and a tackifying resin
CN101291954B (zh) 2005-08-26 2013-03-27 罗氏格黎卡特股份公司 具有改变的细胞信号传导活性的修饰的抗原结合分子
AR062223A1 (es) * 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
US20090017050A1 (en) * 2007-07-13 2009-01-15 Ventana Medical Systems, Inc. Egfr antigen-binding molecules and uses thereof
RU2011116112A (ru) * 2008-09-26 2012-11-10 Роше Гликарт Аг (Ch) Биспецифические анти-egfr/анти-igf-1r антитела

Also Published As

Publication number Publication date
US20080279858A9 (en) 2008-11-13
KR101467566B1 (ko) 2014-12-02
RU2007133439A (ru) 2009-03-20
AR052285A1 (es) 2007-03-07
US7722867B2 (en) 2010-05-25
RU2013119417A (ru) 2014-11-10
AU2006211037B2 (en) 2012-05-24
BRPI0607315A2 (pt) 2009-09-01
US20200332012A1 (en) 2020-10-22
CR20120587A (es) 2013-02-05
US20140227253A1 (en) 2014-08-14
HRP20192134T1 (hr) 2020-02-21
JP5336089B2 (ja) 2013-11-06
TWI387602B (zh) 2013-03-01
CR9236A (es) 2007-11-23
US20110111461A1 (en) 2011-05-12
US8614065B2 (en) 2013-12-24
TW200639181A (en) 2006-11-16
HK1110873A1 (en) 2008-07-25
MA29279B1 (fr) 2008-02-01
JP2013165711A (ja) 2013-08-29
KR101569300B1 (ko) 2015-11-13
EP3660049A1 (en) 2020-06-03
IL184498A0 (en) 2007-10-31
ES2755976T3 (es) 2020-04-24
US20160304614A1 (en) 2016-10-20
EP2404937A1 (en) 2012-01-11
WO2006082515A3 (en) 2007-06-14
PT1871805T (pt) 2019-12-02
US20060269545A1 (en) 2006-11-30
PL1871805T3 (pl) 2020-03-31
US8097436B2 (en) 2012-01-17
AU2006211037A1 (en) 2006-08-10
KR20140031985A (ko) 2014-03-13
CN101115773B (zh) 2015-06-10
BRPI0607315B1 (pt) 2022-05-17
IL184498A (en) 2011-08-31
EP2402374A1 (en) 2012-01-04
RU2488597C2 (ru) 2013-07-27
NZ556286A (en) 2010-11-26
MX2007008619A (es) 2007-09-11
CN103981190A (zh) 2014-08-13
KR20070119629A (ko) 2007-12-20
SI1871805T1 (sl) 2020-02-28
US7846432B2 (en) 2010-12-07
US20190106497A1 (en) 2019-04-11
RU2610688C2 (ru) 2017-02-14
US20090186019A1 (en) 2009-07-23
UA95068C2 (uk) 2011-07-11
NO20073662L (no) 2007-11-05
EP1871805A2 (en) 2008-01-02
DK1871805T3 (da) 2019-12-02
JP2008529489A (ja) 2008-08-07
JP5763695B2 (ja) 2015-08-12
US9309317B2 (en) 2016-04-12
EP1871805B1 (en) 2019-09-25
CN101115773A (zh) 2008-01-30
US20120178106A1 (en) 2012-07-12
WO2006082515A2 (en) 2006-08-10
RS59761B1 (sr) 2020-02-28
LT1871805T (lt) 2019-12-10
CA2596835C (en) 2019-08-20
US9957326B2 (en) 2018-05-01
CA2596835A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
IL184498A0 (en) Antigen binding molecules that bind egfr, vectors encoding same , and uses thereof
HK1131163A1 (en) Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
HRP20190312T1 (hr) Vežući proteini, uključujući protutijela, derivate protutijela i fragmente protutijela, koji se specifično vežu na cd154 i njihova upotreba
HK1253391A1 (zh) 與161p2f10b蛋白結合的抗體和相關分子
HRP20150074T1 (hr) Humana antitijela koja se vežu za mezotelin i njihove uporabe
IL188345A (en) A binding protein specific to cd37
IL211132A0 (en) Anti-il-6 antibodies, compositions, methods and uses
EP1846032A4 (en) LUCA2 AND ANTIBODY BINDING
HK1107402A1 (en) Kid31 and antibodies that bind thereto kid31
IL202259A0 (en) Antigen binding proteins that bind par-2
PL1871804T3 (pl) Przeciwciała wiążące CCX-CKR2
ZA200709303B (en) Antibodies and related molecules that bind to 161P2F210B proteins
ZA201000706B (en) Antigen binding proteins that bind par-2
GB0511881D0 (en) Binding molecules